Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.790
+0.050 (2.87%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Gain Therapeutics Employees
As of December 31, 2024, Gain Therapeutics had 25 total employees, including 23 full-time and 2 part-time employees. The number of employees decreased by 7 or -21.88% compared to the previous year.
Employees
25
Change (1Y)
-7
Growth (1Y)
-21.88%
Revenue / Employee
n/a
Profits / Employee
-$816,448
Market Cap
50.02M
Employees Chart
GANX News
- 21 days ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire
- 22 days ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - GlobeNewsWire
- 2 months ago - Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
- 4 months ago - Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - GlobeNewsWire